Abstract | OBJECTIVE: METHODS: We therefore investigated the effect of a high-dose application of fluvastatin on biliary lipid composition in 21 subjects exhibiting mild hypercholesterolaemia and a history of current gallstones or cholecystectomy due to gallstone disease. Subjects were treated either with 40 mg fluvastatin twice per day over a 3-month period (n = 14) or with placebo (n = 7). Bile samples were aspirated during endoscopy after intravenous ceruletid stimulation before and after therapy. RESULTS: Both groups were comparable in CSI (mean +/- SD) at baseline (1.78 +/- 0.2 placebo vs. 1.97 +/- 0.4 verum). CSI significantly decreased in the verum group to 1.45 +/- 0.4 (P = 0.003) mainly due to increased phospholipid levels, whereas no difference was observed in the placebo group (1.85 +/- 0.7, n.s.). In addition, the verum group exhibited a significant reduction of hydrophobic deoxycholic acid, which has been reported to induce cholesterol crystal precipitation, and an increase of hydrophilic cholic acid. CONCLUSION:
|
Authors | M Porsch-Ozçürümez, P D Hardt, H Schnell-Kretschmer, K von Bergmann, C Darui, J Nonhoff, C Abletshauser, H U Klör |
Journal | European journal of clinical pharmacology
(Eur J Clin Pharmacol)
Vol. 56
Issue 12
Pg. 873-9
(Mar 2001)
ISSN: 0031-6970 [Print] Germany |
PMID | 11317474
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Bile Acids and Salts
- Fatty Acids, Monounsaturated
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Indoles
- Fluvastatin
|
Topics |
- Aged
- Bile Acids and Salts
(blood, metabolism)
- Cholelithiasis
(prevention & control)
- Double-Blind Method
- Fatty Acids, Monounsaturated
(therapeutic use)
- Female
- Fluvastatin
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Hypercholesterolemia
(drug therapy)
- Indoles
(therapeutic use)
- Male
- Middle Aged
|